Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-α antibody therapy

CER3247
2008 Vol.26, N°2
PI 0261, PF 0267
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 18565247 [PubMed]

Abstract

OBJECTIVES:
To investigate the mechanism of action of anti-tumor necrosis factor-α (TNF-α) antibody in patients with rheumatoid arthritis (RA), we analyzed serum or plasma proteins by mass spectrometry system.
METHODS:
Ten RA patients who received treatment with anti-TNF-α antibody were studied. Samples obtained before and after therapy were analyzed by a two-dimensional liquid chromatography tandem mass spectrometry (2D LC-MS/MS) system after pretreatment by a recently developed method to remove high molecular weight proteins.
RESULTS:
Using this system, certain proteins were identified after treatment with anti-TNF-α antibody, including proteins related to the TNF-α-mediated pathway for nuclear factor kappa B (NF-κB) activation and/or to the metabolism (including regeneration) of articular cartilage.
CONCLUSIONS:
Our mass spectrometry system appears to be useful for proteomic analysis. The efficacy of anti-TNF-α antibody therapy for RA may be related to various consequence of the inhibition of TNF-α activity.